Cycle and Care
Live
Menopause

ASA bans Voy testosterone adverts for misleading claims

The UK advertising regulator has banned five adverts for Voy's at-home testosterone tests for misleadingly linking common symptoms like low energy and irritability to low testosterone, citing a lack of evidence.

The UK advertising regulator has banned five adverts for Voy's at-home testosterone tests for misleadingly linking common...

The Advertising Standards Authority has banned five adverts from online health platform Voy for making misleading claims about low testosterone. The banned materials, which included three posters and two paid Facebook ads, linked symptoms like low sex drive, fatigue, loss of motivation, and mood changes to low testosterone levels.

The ASA investigation, triggered by public complaints, found a recurring theme of advertisers exploiting insecurities around libido, erectile problems, and ageing. One specific Facebook ad claimed that 'low testosterone sneaks up on 1 in 4 men over 30'. The regulator called that claim misleading and unsupported by the evidence Voy provided.

Voy, a prominent seller of weight loss treatments like Mounjaro and Wegovy, withdrew the adverts during the investigation and confirmed they will not run the campaigns again. The company disputed the ASA's ruling, arguing its ad language was deliberately conditional and did not state symptoms were definitively caused by low testosterone.

The misleading claims

The ASA stated the adverts exaggerated the connection between low testosterone and common symptoms. It ruled that symptoms such as irritability and fatigue are much less specific and can have many possible causes. Presenting them in isolation as strong indicators of low testosterone was therefore misleading.

The investigation highlighted that while advertising for low-testosterone tests and services is permitted, claims must be accurate and backed by strong evidence. The authority instructed Voy to ensure future campaigns do not mislead people about low-testosterone symptoms or how common the condition is.

Voy's response and clarification

Voy disputed the ASA's findings. Dr Earim Chaudry, chief medical officer for Voy, stated that every patient decision at the company is clinician-led and that the campaigns were developed to align with UK advertising standards. He added that Voy keeps all its advertising under continual review to ensure it meets any updated guidance.

Some of Voy's testosterone test kit adverts had drawn backlash online earlier this year when they appeared on the London Underground. Critics described them as 'ragebait' for using phrases like 'It's not him, it's his hormones' and 'Men get hormonal too'. Voy said it was trying to destigmatise conversations about men's health.

ASA's regulatory stance

Catherine Drewett, investigations manager at the ASA, emphasized that people must be able to trust health claims in advertising. The ruling reinforces that health claims in ads require robust evidence and clarifies standards for businesses promoting tests and services. The regulator noted that symptoms should not be presented as strong indicators of low testosterone in isolation.

This ruling follows two other actions in August against companies for misleading testosterone testing claims. The ASA ruled against BioID Health over Facebook adverts promoting hormone therapy and low-testosterone testing. It also banned an advert by Numan Digital Healthcare that falsely claimed '40 per cent of men with obesity have low testosterone'.

The NHS states that testosterone levels in men fall as they age, but this is unlikely to cause problems in itself. Dr Richard Quinton, an expert in testosterone deficiency, noted it is very easy to get a low testosterone reading in any healthy man from factors like an afternoon blood test, eating a meal, being unwell, or staying up all night.

Voy will not run the banned campaigns again, as confirmed by their withdrawal during the investigation and commitment to future compliance with ASA standards.

Related coverage

More from Menopause